Peter R. Galle, MD, PhD, Mainz University Medical Center

Articles by Peter R. Galle, MD, PhD, Mainz University Medical Center

HCC Global Screening Programs for At-Risk Populations

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

HCC Etiologic Risk Factors and Global Prevalence

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Dr. Galle on Patient-Reported Outcomes From the Phase III IMbrave150 Trial

ByPeter R. Galle, MD, PhD, Mainz University Medical Center

January 26th 2020

Peter R. Galle, MD, discusses the patient-reported outcomes results from the Phase III IMbrave150 study, which he presented at the 2020 Gastrointestinal Cancers Symposium

Peter R. Galle, MD, PhD, Mainz University Medical Center

Articles by Peter R. Galle, MD, PhD, Mainz University Medical Center

HCC Global Screening Programs for At-Risk Populations

HCC Etiologic Risk Factors and Global Prevalence

Dr. Galle on Patient-Reported Outcomes From the Phase III IMbrave150 Trial

Trending on OncLive

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer

CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma

FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma

pTVG-HP DNA Vaccine Extends Overall Survival vs Placebo in PSA-Recurrent Prostate Cancer

FDA Grants Breakthrough Therapy and Fast Track Status to 68Ga-NYM096 in ccRCC